Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Department of Cardiovascular Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
J Heart Lung Transplant. 2020 May;39(5):412-417. doi: 10.1016/j.healun.2020.03.008. Epub 2020 Mar 25.
The epidemiologic and clinical characteristics of heart transplant (HTx) recipients during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic remains unclear. We studied the characteristics of HTx recipients from December 20, 2019, to February 25, 2020, in an effort to understand their risk and outcomes.
All accessible HTx recipients were included in this single-center retrospective study. We collected information on the recipients using a web-based questionnaire as well as the hospital database.
We followed 87 HTx recipients (72.4% were men, and the average age was 51 years). A total of 79 recipients resided in Hubei, and 57 recipients had a Wuhan-related history of travel or contact. Most took precautionary measures while in contact with suspicious crowds, and 96.6% of the families and communities undertook prevention and quarantine procedures. Four upper airway infections were reported, and 3 of them tested negative for SARS-CoV-2 (the fourth recovered and was not tested). All cases were mild and successfully recovered after proper treatment. Laboratory results of 47 HTx cases within the last 2 months were extracted. Of these, 21.3% of recipients had pre-existing lymphopenia, and 87.2% of recipients had a therapeutic concentration of tacrolimus (5-12 ng/ml). Liver and kidney insufficiency was seen in 5 and 6 recipients, respectively.
HTx recipients who practiced appropriate prevention measures had a low rate of infection with SARS-CoV-2 and transition to the associated disease COVID-19. These early data will require confirmation as the pandemic establishes around the world.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)流行期间,心脏移植(HTx)受者的流行病学和临床特征尚不清楚。我们研究了 2019 年 12 月 20 日至 2020 年 2 月 25 日期间 HTx 受者的特征,以了解他们的风险和结局。
本单中心回顾性研究纳入了所有可获得的 HTx 受者。我们使用基于网络的问卷调查和医院数据库收集受者信息。
我们随访了 87 例 HTx 受者(72.4%为男性,平均年龄为 51 岁)。共有 79 例受者居住在湖北,57 例受者有武汉相关旅行或接触史。大多数受者在接触可疑人群时采取了预防措施,96.6%的家庭和社区采取了预防和检疫措施。报告了 4 例上呼吸道感染,其中 3 例 SARS-CoV-2 检测结果为阴性(第 4 例已康复,未进行检测)。所有病例均为轻症,经适当治疗后均成功康复。提取了最近 2 个月内的 47 例 HTx 病例的实验室结果。其中,21.3%的受者存在预先存在的淋巴细胞减少症,87.2%的受者他克莫司(5-12ng/ml)治疗浓度。分别有 5 例和 6 例受者出现肝肾功能不全。
采取适当预防措施的 HTx 受者 SARS-CoV-2 感染率较低,且向相关疾病 COVID-19 转化的比例较低。随着全球大流行的发展,这些早期数据需要进一步确认。